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Abstract 
Background/Aims: Resistance to genotoxic therapy is a characteristic feature 
of glioma cells. Acid sphingomyelinase (ASM) hydrolyzes sphingomyelin to 
ceramide and glucosylceramide synthase (GCS) catalyzes ceramide 
metabolism. Increased ceramide levels have been suggested to enhance 
chemotherapy-induced death of cancer cells.  
Methods: Microarray and clinical data for ASM and GCS in astrocytomas 
WHO grade II – IV were acquired from the Rembrandt database. Moreover, 
the glioblastoma database of the Cancer Genome Atlas network (TCGA) was 
used for survival data of glioblastoma patients. For in vitro studies, increases 
in ceramide levels were achieved either by ASM overexpression or by the 
GCS inhibitor DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol 
(PPMP) in human glioma cell lines. Combinations of alkylating chemotherapy 
or irradiation and ASM overexpression, PPMP or exogenous ceramide were 
applied in parental cells. The anti-glioma effects were investigated by 
assessing proliferation, metabolic activity, viability and clonogenicity. Finally, 
viability and clonogenicity were assessed in temozolomide (TMZ)-resistant 
cells upon treatment with PPMP, exogenous ceramide, alkylating 
chemotherapy, irradiation or their combinations. 
Results: Interrogations from the Rembrandt and TCGA database showed a 
better survival of glioblastoma patients with low expression of ASM or GCS. 
ASM overexpression or PPMP treatment alone led to ceramide accumulation 
but did not enhance the anti-glioma activity of alkylating chemotherapy or 
irradiation. PPMP or exogenous ceramide induced acute cytotoxicity in 
glioblastoma cells. Combined treatments with chemotherapy or irradiation led 
to additive, but not synergistic effects. Finally, no synergy was found when 
TMZ-resistant cells were treated with exogenous ceramide or PPMP alone or 
in combination with TMZ or irradiation. 
Conclusion: Modulation of intrinsic glioma cell ceramide levels by ASM 
overexpression or GCS inhibition does not enhance the anti-glioma activity of 
alkylating chemotherapy or irradiation.  
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Introduction 
 
Glioblastoma is the most common primary malignant brain tumor [1]. Despite 
multimodal therapy the median overall survival does not exceed 11 months in 
population-based studies [2] or 15 months in selected clinical trial populations 
[3,4]. The current standard of care for newly diagnosed glioblastoma includes 
radiotherapy (RT) with concomitant and maintenance temozolomide (TMZ) 
chemotherapy [5]. The nitrosoureas N-(2-chloroethyl)-N'-cyclohexyl-N-
nitrosourea (CCNU) or N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU) are now 
commonly applied in recurrent glioblastoma [6,7,8]. A major therapeutic 
challenge remains the primary or acquired resistance of glioma cells to RT  
and/or alkylating agents, e.g. TMZ or CCNU. Therefore, new strategies to 
overcome the resistance to these therapeutic strategies are urgently needed. 
Modulation of the sphingolipid signaling cascade had been suggested as a 
promising strategy to overcome resistance to anti-cancer therapies [9,10]. 
Acid sphingomyelinase (ASM) is a glycoprotein localized in classical or 
secretory lysosomes that catalyses the hydrolysis of sphingomyelin to 
ceramide [11]. This results in the formation of ceramide-enriched membrane 
platforms and clustering of death receptors leading to apoptosis [11,12]. ASM-
induced ceramide accumulation induced apoptosis in response to the 
activation of pro-apoptotic receptor proteins, e.g. cluster of differentiation 95 
(CD95) [13,14,15] or tumor necrosis factor receptor [16]. Several stress 
stimuli can also activate ASM signaling, e.g. irradiation [17,18], ultraviolet light 
[19] and chemotherapeutic drugs. Smith and Schuchman analyzed the 
microarray database Oncomine (www.oncomine.org) in 2008 and concluded 
that in some cancers ASM may be down-regulated, causing reduced 
ceramide levels [9]. Chemotherapy-induced ASM activation and apoptosis 
were demonstrated in human colon cancer cell lines after cisplatin therapy 
[20], in human ovarian cancer cells upon paclitaxel therapy [21] and in 
neuroblastoma cells upon fenretinide treatment [22]. ASM overexpression 
sensitized the murine glioma cell line GL-261 and the human glioma cell line 
U373MG to gemcitabine or doxorubicin [23]. ASM expression in U87MG 
glioma cells was found to be p53-independent and sensitized these cells to 
irradiation [24].  
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Ceramide levels are low in several tumor types compared to non-maligant 
tissue, including colon cancer [25] and ovarian cancer [26]. Riboni et al. 
suggested that ceramide levels decrease during malignant progression of 
human gliomas [27]. Recently the same group proposed that TMZ increases 
endogenous ceramide in human glioblastoma cell lines in vitro but not in TMZ-
resistant cells [28]. We previously demonstrated that exogenous C2-ceramide 
induced apoptosis in human glioma cell lines and that the combination of C2-
ceramide and CD95L induced cell death synergistically in T98G and LNT-229 
glioma cells [29]. 
Overexpression of glucosylceramide synthase (GCS), an enzyme leading to 
ceramide degradation, enhanced resistance to doxorubicin in breast cancer 
cell lines. Inhibitors of GCS restored sensitivity of these cells to chemotherapy 
[30,31]. The inhibition of GCS also sensitized mouse glioma cells to 
gemcitabine [32]. Similar results were published for TMZ-resistant human 
glioblastoma cells [28]. Synergistic effects of GCS inhibition and 
chemotherapeutic drugs were also demonstrated for neuroblastoma, 
melanoma, prostate, lung, colon and pancreatic cancer [33,34]. Moreover, 
overexpression of GCS was found in chemoresistant leukemia cells [35]. On 
the other hand, several groups defined limitations of the role of GCS for 
resistance to cancer chemotherapy [36,37,38].  
Based on these data, we investigated the impact of modulating endogenous 
ceramide levels on the resistance to clinically relevant therapies at clinically 
relevant concentrations respectively doses in LNT-229 and T98G human 
glioma cells lines in vitro. Modulations of the endogenous ceramide pathway 
were achieved either by stable ASM overexpression or by inhibition of GCS 
using the specific inhibitor DL-threo-1-phenyl-2-palmitoylamino-3-consumption 
(PPMP) [39]. Finally exogenous ceramide analogs were used, too. As 
treatment modalities, we used clinically relevant concentrations of alkylating 
agents, i.e. TMZ and CCNU, as well as clinically relevant doses of irradiation. 
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Materials and Methods 
 
Cells and reagents 
The human malignant glioma cell line T98G was obtained from the American 
Type Culture Collection (Rockville, MD). LNT-229 cells and LN-18 cells were 
kindly provided by N. de Tribolet (Lausanne, Switzerland) and have been 
used in previous studies of our laboratory [40]. TMZ-resistant cells were 
generated by repetitive exposure of LNT-229 and LN-18 glioma cells to TMZ. 
The TMZ-resistant cells are referred to as LN-18_R and LNT-229_R and have 
been characterized in our laboratory [41]. The cells were maintained in 
Dulbecco's modified eagle medium (DMEM) containing 10% fetal calf serum 
(FCS) (Biochrom KG, Berlin, Germany) and 2 mM glutamine and 
penicillin/streptomycin. A monoclonal antibody to human ASM suitable for 
immunoblotting was purchased from Cell Signaling Technology (Boston, MA, 
catalogue number 3687, source rabbit). The antibody to β-actin was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA, catalogue number sc-1616-
R, source rabbit) and the antibody to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was obtained from Everest Biotech (Ramona, CA, 
USA, catalogue number EB06377). The GCS antibody was purchased from 
Abcam (Cambridge, United Kingdom, catalogue number 3687, ab98030, 
source rabbit). TMZ was obtained from Schering-Plough (Kenilworth, NJ, 
USA) and stock solutions were prepared in dimethylsulfoxide. C2-ceramide 
(N-acetyl-D-sphingosine), C6-ceramide (N-hexanoyl-D-sphingosine), PPMP 
(DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol) and ami-
triptyline were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
Lentiviral production, titration and transduction 
A lentiviral backbone containing an enhancing green fluorescent protein 
(eGFP) cassette driven by an internal spleen focus forming virus (SFFV) 
promoter and containing an additional pIRES sequence, lenti-SIEW (spleen 
focus forming virus promoter, pIRES, eGFP, WPRE), was kindly provided by 
Manuel Grez [42]. The ASM sequence was cloned into lenti-SIEW. Both 
strands of the final pSIEW-ASM were analyzed to verify the correct DNA 
sequence. Lentivirus was produced as previously described [43]. Briefly, the 
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lentivirus was generated by co-transfecting 293T cells with the vector and the 
packaging constructs. Supernatants of these cells, containing the lentivirus, 
were collected 48 and 72 hours (h) after co-transfection. Supernatants were 
concentrated by ultracentrifugation and used directly to transduce target cells 
with 100 transducing units per ml in 24-well plates. 
 
Real-time polymerase chain reaction (RT-PCR) 
Total RNA was prepared using the NucleoSpin System (Macherey-Nagel AG, 
Oensingen, Switzerland) and transcribed according to standard protocols. 
cDNA was prepared using Superscript RNase H reverse transcriptase 
(Invitrogen, Paisley, UK) and random hexamers (Sigma-Aldrich). For RT-
PCR, cDNA amplification was measured using the 7300 Real-time PCR 
System (Applied Biosystems, Zug, Switzerland) with SYBR Green Master Mix 
(Eurogentec, Cologne, Germany) and primers (Metabion, Martinsried, 
Germany) at optimized concentrations. ADP-ribosylation factor 1 (ARF1) or 
GAPDH were used as housekeeping genes [44]. The following primers were 
used: ARF1, forward 5’-GAC CAC GAT CCT CTA CAA GC-3’, reverse 5’-
TCC CAC ACA GTG AAG CTG ATG-3’; GAPDH, forward 5’-CTC TCT GCT 
CCT CCT GTT CGA C-3’, reverse 5’-TGA GCG ATG TGG CTC GGC T-3’; 
ASM, forward 5’-TAC ATC GCA TAG TGC CCC GGC T-3’, reverse 5’-CCC 
ACG CGA GCC ACA TTG GGT-3’; GCS, forward 5’-ATG ACA GAA AAA 
GTA GGC TTG G-3’, reverse 5’-GGA CAC CCC TGA GTT GAA-3’. Relative 
quantification of gene expression was determined by comparison of threshold 
values. All results were normalized to ARF1 and calculated with the ΔCTT 
method for relative quantification [45]. 
 
Immunoblot analysis 
For the detection of proteins from cell lysates, cells were lysed in 
radioimmunoprecipitation assay buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1% 
NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulphate) supplemented 
with 1x complete inhibitor mix (Roche Diagnostics, Grenzach-Wyhlen, 
Germany), and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich). 
Protein concentrations were measured with the Bradford protein assay 
reagent (Bio-Rad Laboratories, Hercules, California, USA) with bovine serum 
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albumin as a standard. Protein levels were analyzed by immunoblot using 20 
µg of protein per lane mixed with Laemmli buffer containing β-
mercaptoethanol unless otherwise indicated with the respective antibodies in 
the concentrations recommended by the manufacturer. Equal protein loading 
was ascertained by Ponceau S (Sigma Aldrich) staining. Visualization of 
protein bands was accomplished using horseradish peroxidase-coupled 
secondary antibodies (Santa Cruz) and enhanced chemiluminescence 
(Perbio, Bonn, Germany). 
 
Acute cytotoxicity assay 
Five thousand cells were seeded per well in 96-well plates and allowed to 
attach for 24 h. The cells were treated with the respective agent for 24 h 
under serum-free conditions. 72 h later the cell culture medium was removed 
and surviving cells were stained with crystal violet and optical density values 
were read in an ELISA reader at 560 nm wavelength. 
 
Clonogenic survival assay 
Five hundred cells were seeded per well in 6-well plates in DMEM/10% FCS. 
Medium was removed after 24 h and cells were treated in serum-free medium 
with the respective reagents for 24 h and then kept in medium supplemented 
with 10% FCS. When clones were detected by microscopy, the medium was 
removed, and the number of colonies was quantified using crystal violet 
staining.  
 
Cell proliferation assay 
Proliferation assays were performed as previously described [46]. In brief, 
1.000 cells were seeded per well (24-well pate) in DMEM/10% FCS. Cells 
were counted every 24 h up to 7 days using trypan blue staining.  
 
Alamar Blue assay 
Metabolic activity was assessed using the Alamar Blue Assay (Invitrogen). 
10.000 cells were seeded per well (96-well plate) in DMEM/10% FCS. 24 h 
later the mix-and-ready Alamar Blue Solution was added in each well for 4 h. 
Absorbance was measured at 570 nm. The amount of absorbance is 
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proportional to the number of living cells and corresponds to the cellular 
metabolic activity [47]. 
 
Gene expression analysis and Kaplan Meier analysis of survival probability 
using Rembrandt database and the Cancer Genome Atlas network 
Microarray and clinical data were obtained from the Repository for Molecular 
BRAinNeoplasiaDaTa (Rembrandt) using data available on August 04, 2011 
(https://caintegrator.nci.nih.gov/rembrandt/) [48] and from the glioblastoma 
data set of the Cancer Genome Atlas network available on December 01, 
2012 (http://cancergenome.nih.gov/) [49]. Gene expression data in both 
glioma databases were collected using Affymetrix gene chips. The query in 
both databases was based on the reporter with the highest mean geometric 
intensity for the target gene (ASM: 209420_s_at; GCS: 204881_s_at). The 
Rembrandt database provides data of patients diagnosed for astrocytoma 
WHO grade II – IV. The group of glioblastoma patients in this database 
includes 228 cases. In addition, we also used the TCGA database and 
analyzed data from 504 glioblastoma patients. 
Gene expression and Kaplan-Meier survival data for ASM or GCS were 
queried following the Rembrandt site’s instructions for „advanced search“ and 
via the caINTEGRATOR homepage (https://caintegrator2.nci.nih.gov) 
following the site’s instructions. The sample group for gene expression was 
restricted to astrocytomas WHO grade II/III (n = 148) and glioblastomas (n = 
228) and compared to normal brain tissues (n = 28). Survival data for the 
Kaplan-Meier analysis using the Rembrandt database were available from 
patients diagnosed with astrocytoma WHO grade II/III (n = 162) and 
glioblastoma (n = 181). Samples with a 2-fold up-regulation or a 2-fold down-
regulation of the target gene compared to normal brain tumor tissue were 
defined as up- or down-regulated, the other samples were defined as 
intermediate.  
Survival analysis within the glioblastoma data set of the TCGA database 
(n=504) was performed using the Kaplan-Meier analysis module of the R2 
microarray analysis and visualization platform (http://r2.amc.nl). The averaged 
mRNA expression staining for ASM was scaled to 65 for ASM and 299 for 
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GCS. The cut-off for the highest impact on survival was 39.3 for ASM and 216 
for GCS. This cut-off divides the glioblastoma patients in two groups with high 
or low expression of the target gene. 
 
ASM activity 
ASM activity was determined as described [23]. Briefly, 200,000 cells were 
seeded per well (6-well plate) and allowed to attach for 24 h. Cells were lysed 
in a buffer consisting of 250 mM sodium acetate (pH 5.0), 1% NP-40, 1.3 mM 
ethylenediaminetetraacetic acid (EDTA), diluted to 0.1% NP40, and incubated 
with 50 nCi [14C]-sphingomyelin per sample (Perkin Elmer, Waltham, MA, 
USA; 52 mCi/mmol) for 30 min at 37°C. The substrate was dried prior to the 
assay, resuspended in 250 mM sodium acetate (pH 5.0), 0.1% NP-40, 1.3 
mM EDTA and sonicated for 10 min in a bath sonicator to obtain micelles. The 
reaction was stopped by the addition of 800 µL chloroform/methanol (2:1, v/v), 
and phases were separated by centrifugation. Radioactivity of the aqueous 
phase was measured by using liquid scintillation counting to determine the 
release of [14C]phosphorylcholine from [14C]sphingomyelin as a measure of 
ASM activity.   
 
Ceramide measurements 
Ceramide concentrations were determined by DAG kinase assays as 
described [50]. Glioma cells were treated with PPMP, irradiation or TMZ. 
Medium was removed 12 h later and the cells were lysed in 300 microliter 
methanol, homogenized by tip sonication, brought to CHCl3:CH3OH:1N HCl 
(100:100:1, v/v/v) and 200 µL H2O were added. The samples were vortexed, 
the phases were separated, the lower phase was collected, dried, 
resuspended in 20 µL of a detergent solution (7.5% [w/v] n-octyl 
glucopyranoside, 5 mM cardiolipin in 1 mM diethylenetriaminepentaacetic acid 
[DTPA]), and sonicated for 10 min. The kinase reaction was started by the 
addition of 70 µL of a reaction mixture containing 10 µL diacylglycerol (DAG) 
kinase (GE Healthcare Europe, Munich, Germany), 0.1 M imidazole/HCl (pH 
6.6), 0.2 mM DTPA (pH 6.6), 70 mM NaCl, 17 mM MgCl2, 1.4 mM ethylene 
glycol tetraacetic acid, 2 mM dithiothreitol, 1 µM adenosine triphosphate 
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(ATP), and 5 µCi [32P]ATP. The kinase reaction was performed for 30 min at 
room temperature and terminated by the addition of 1 mL CHCl3:CH3OH:1N 
HCl (100:100:1, v/v/v), 170 µL buffered saline solution (135 mM NaCl, 1.5 mM 
CaCl2, 0.5 mM MgCl2, 5.6 mM glucose, 10 mM HEPES [pH 7.2]), and 30 µL 
of a 100 mM EDTA solution. The lower phase was collected, dried, and 
separated on Silica G60 thin-layer chromatography (TLC) plates with 
chloroform/acetone/methanol/acetic acid/H2O (50:20:15:10:5, v/v/v/v/v). The 
TLC plates were exposed to radiography films, the spots were removed from 
the plates, and the incorporation of [32P] into ceramide was measured by 
liquid scintillation counting. Ceramide amounts were determined by 
comparison with a standard curve using C16 to C24 ceramides as substrates. 
Ceramide amounts were normalized to protein concentrations. 
 
Statistics 
Analysis of significance was performed using the two-tailed Student’s t-test (t-
test) (Excel, Microsoft, Redmond, Washington, USA). For Kaplan-Meier 
survival analysis the log-rank test was used. All experiments were done at 
least three times and at least one representative experiment is shown. To 
study if co-treatments show additive or synergistic results, the fractional 
product method was used. The effect of two independently acting agents is 
defined as the product of the unaffected fractions after treatment with either 
agent alone, named the predicted value. If the observed value of the co-
treatment exceeds that of the calculated product, the two agents show 
synergy [51,52]. 
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Results 
 
ASM and GCS expression and clinical outcome in glioma patients 
In this study we modified the activity of two proteins, ASM and GCS, with the 
aim to increase endogenous ceramide levels in human glioma cells in vitro 
and to investigate the impact of intrinsic ceramide levels on resistance to 
TMZ, CCNU or irradiation. First, we explored the potential role of these two 
genes in glioma patients using the Rembrandt and TCGA databases.  
First we analyzed the mRNA expression of ASM in glioma patients in the 
Rembrandt database, showing that ASM mRNA levels did not differ in human 
glioblastomas or astrocytomas WHO grade II/III compared to normal brain 
(Fig. 1A). Interestingly, the survival analysis revealed that the overall survival 
of patients with glioma (WHO grades II-IV) with a more than 2-fold increase of 
ASM was reduced in comparison with patients with intermediate expression, 
but this analysis is limited by the fact that only 7 patients showed increased 
levels of ASM mRNA (Fig. 1B). A downregulation of ASM mRNA more than 2-
fold, on the other hand, was not detected in the Rembrandt database. Next, 
we analyzed the clinical outcome data in glioblastoma patients in the 
Rembrandt database. Five patients showed a more than 2-fold ASM increase 
compared to normal brain tissue without any correlation to the probability of 
survival (Fig. 1C). Therefore, we investigated a larger group of glioblastoma 
patients and analyzed the TCGA database for a statistically ideal cut-off, 
dividing the group of glioblastoma patients in patients with a high and patients 
with a low expression of ASM. Kaplan-Meier curves derived from the TCGA 
database demonstrated longer survival of glioblastoma patients with low 
levels of ASM (Fig. 1D). Taken together, interrogations of the Rembrandt and 
TCGA database did not establish a strong correlation between loss of ASM 
expression and poor outcome. 
Next, we assessed the gene expression of GCS in the same samples of 
glioma patients in the Rembrandt database, showing that GCS mRNA 
expression was not differentially regulated in human glioblastoma tissues 
compared to normal brain (Fig. 1E). In the sample group of astrocytomas 
grade II/III GCS mRNA levels were significantly lower than in glioblastoma 
tissue but also compared to normal brain tissue. Analysis of the Rembrandt 
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database revealed that the overall survival of patients with glioma (WHO 
grades II-IV) with a more than 2-fold increase of GCS was significantly 
reduced and with a more than 2-fold decrease of GCS significantly prolonged 
in comparison with patients with intermediate expression of this gene (Fig. 
1F). Regarding GCS expression in the group of glioblastoma patients, only a 
small group of 10 patients showed a more than 2-fold GCS upregulation, 
associated with a significant decrease in probability of survival, whereas only 
one patient was found in the Rembrandt database showing a more than 2-fold 
reduced GCS mRNA expression. In line with these data, analysis of the 
TCGA database revealed that in patients with glioblastoma, high expression 
of the GCS gene was associated with decreased overall survival (Fig. 1H). 
Taken together, these data suggest a correlation between high GCS 
expression and early death.  
 
Stable overexpression of ASM increases ceramide levels in human glioma 
cell lines, but does not alter proliferation, metabolic activity or clonogenicity 
The two human glioma cell lines LNT-229 and T98G were stably lentivirally 
transduced with SIEW-ASM or control virus. The lentiviral transduction 
efficacy with the GFP-positive SIEW construct was confirmed by fluorescence 
microscopy (Fig. 2A) and flow cytometry (Fig. 2B). Real-time PCR showed a 
strong increase of ASM mRNA levels in both ASM-overexpressing cell lines, 
LNT-229-SIEW-ASM and T98G-SIEW-ASM. The increase of ASM mRNA was 
up to 7-fold in LNT-229 and 14-fold in T98G (Fig. 2C). ASM protein levels 
were determined by immunoblot (Fig. 2D). Three forms of ASM are 
detectable, at 72 kDa, 70 kDa and 57 kDa. The 57 kDa form is probably 
generated by proteolytic cleavage inside the endoplasmatic reticulum/ Golgi 
complex whereas the lysosomal predominant mature 70 kDa form, processed 
from a 72 kDa precursor form, is exclusively processed inside acidic 
organelles [53]. The 72 and 70 kDa forms were dominantly detected in ASM-
overexpressing cells, whereas the 57 kDa form was seen in all transduced 
and non-transduced cell lines and was even decreased in T98G-SIEW-ASM 
(Fig. 2D). ASM protein levels for the 70 kDa form did not change in LNT-229-
SIEW-ASM. ASM overexpression resulted in increased ASM activity, an 
induction of 1.9-fold in LNT-229 and 5.4-fold in T98G, measured as release of 
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phosphorylcholine from sphingomyelin, was observed. ASM overexpression 
led to an increase of intracellular endogenous ceramide levels, up to 3-fold in 
LNT-229 and 2.3-fold in T98G. ASM protein overexpression alone had no 
effect on proliferation (Fig. 2E), metabolic activity (Fig. 2F) or clonogenicity 
(Fig. 2G, H) in either cell line. 
 
ASM overexpression does not sensitize glioma cells to alkylating agents or 
irradiation in vitro 
We treated LNT-229 (Fig. 3A, C) or T98G (Fig. 3B, D) cells for 24 h with 
increasing concentrations of TMZ (Fig. 3A, B) or CCNU (Fig. 3C, D). The 
medium was removed and cells cultured with new medium for up to 2 weeks. 
As expected [54,55], both drugs, TMZ and CCNU, reduced the clonogenic 
survival in a concentration-dependent manner (Fig. 3A-D). ASM 
overexpression did not affect the clonogenic survival of glioma cells co-
exposed to TMZ or CCNU. Moreover ASM-overexpressing LNT-229 and 
T98G showed unaltered sensitivity to irradiation up to 4 Gy (Gray) (Fig. 3E, 
F). Assuming that a sensitizing effect of ASM overexpression correlates to 
increased ceramide levels in response to chemo- or radiotherapy, ceramide 
levels after treatment with TMZ or irradiation were assessed. Irradiation 
increased ceramide levels up to 1.7-fold in LNT-229 and up to 1.5-fold in 
T98G. TMZ treatment induced ceramide accumulation in both cell lines, LNT-
229 (2.1-fold) and T98-G (2.6-fold). To exclude a very early selection step 
after ASM overexpression promoting the survival of cells resistant to ASM 
activity, ASM was overexpressed in LNT-229 in the presence or absence of 
amitriptyline (final concentration 2.5 µM), an ASM inhibitor. Amitriptyline 
treatment was stopped 24 h before the onset of experiments. Yet, ASM 
overexpression did not affect proliferation or clonogenicity under these 
conditions either (data not shown). 
 
PPMP induces acute cytotoxicity and reduces clonogenic survival in glioma 
cell lines  
A second strategy to increase endogenous ceramide levels was the 
application of PPMP, an inhibitor of GCS, described to sensitize different 
tumor types to chemotherapy or irradiation. First we confirmed that the two 
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glioblastoma cell lines LNT-229 and T98G express the enzyme GCS as 
assessed on mRNA (Fig. 4A) and protein level (Fig. 4B). To confirm the 
biological activity of PPMP, endogenous ceramide levels were measured 12 h 
after treatment with 1 or 10 µM PPMP. In both glioma cell lines ceramide 
levels increased in a concentration-dependent manner up to 2.5-2.8 fold (data 
not shown). The effect of PPMP on glioma cell viability was determined in 
acute cytotoxicity and clonogenicity assays. PPMP induced acute cytotoxicity 
in a concentration-dependent manner and the half-maximal inhibitory 
concentration (IC50) values for PPMP were between 5 and 10 µM (72 h 
treatment) (Fig. 4C). When glioblastoma cells were treated with PPMP in a 
clonogenic survival assay for up to 3 weeks, concentrations between 1 and 2 
µM in LNT-229 and between 5 and 10 µM in T98G reduced clonogenic 
survival up to 50% (Fig. 4D).  
 
Co-treatment with PPMP and TMZ or irradiation shows additive but not 
synergistic effects in vitro 
Clonogenic survival data for LNT-229 (Fig. 5A, C) and T98G (Fig. 5B, D) were 
obtained for treatments with TMZ, PPMP or irradiation alone as well as for co-
treatments with TMZ and PPMP (Fig. 5A, B) or irradiation and PPMP (Fig. 5C, 
D). The fractional product method was used to define predicted values in the 
case of independent actions of PPMP and TMZ or irradiation, respectively. 
These predicted values were compared with the actual clonogenic survival. 
Treatments of TMZ, PPMP or irradiation alone reduced clonogenic survival in 
a concentration-/dose-dependent manner. When co-treatments were used, 
however, the observed values exactly matched the predicted values for 
independent actions. Thus, the combination of PPMP with TMZ or irradiation 
led to additive rather than synergistic effects in both glioma cell lines in a 
clonogenic survival assay. To be sure that sensitizing effects of PPMP and 
irradiation or TMZ do not occur in the first days of treatment and may not be 
detectable in the clonogenic survival assays later, acute cytotoxicity assays 
were performed in addition. Again, no synergistic effects of PPMP in 
combination with TMZ or irradiation were observed in LNT-229 (Fig. 5E) and 
T98G (Fig. 5F) parental cells. 
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Exogenous ceramide induces cytotoxicity and reduces clonogenicity in human 
glioma cell lines, but not synergistically in combination with irradiation or TMZ 
To supplement the data listed above, short chain analogs of ceramide, C2- 
and C6-ceramide were used to mimic autocrine effects of endogenous 
ceramide. We examined the acute and long-term cytotoxic effects of C2- and 
C6-ceramide in LNT-229 and T98G glioblastoma cell lines. Both ceramide 
analogs induced acute cytotoxicity in a concentration-dependent manner (72 
h treatment) (Fig. 6A, B). IC50 values for acute cytotoxicity were around 12 
and 25 µM in both cell lines for C2-ceramide and around 25 and 50 µM for 
C6-ceramide. Lower concentrations of these ceramide analogs were sufficient 
to reduce clonogenic survival in human glioma cell lines, LNT-229 and T98G 
(Fig. 6C, D). Next, clonogenicity data were obtained when human glioma cells 
were co-treated with exogenous ceramide and TMZ (Fig. 7A, B) or irradiation 
(Fig. 7C, D). Again, no synergistic effects were observed in LNT-229 (Fig. 7A, 
C) or T98G cells (Fig. 7B, D) and the observed values matched the predicted 
values for independent activities. Single effects of TMZ, C2-ceramide, C6-
ceramide or irradiation induced reduced clonogenicity in a concentration-
/dose-dependent manner, as expected. Cell viability of LNT-229 (Fig. 7E) and 
T98G (Fig. 7F) cells was also assessed 72 h after treatment with a single 
dose of C2-ceramide, C6-ceramide, TMZ or irradiation. When short chain 
ceramide analogs were used in combination with TMZ or irradiation, no 
significant effects were observed either (Fig. 7E, F). 
 
Exogenous ceramide or PPMP induce acute cytotoxicity and reduce 
clonogenic survival in TMZ-resistant cell lines  
Finally, we investigated the effects of exogenous ceramide or PPMP in human 
glioma cell lines resistant to TMZ. Two cell lines, LNT-229 and LN-18, had 
been exposed repetitively to increasing concentrations of TMZ until a stable 
resistant phenotype (LNT-229_R and LN-18_R) was induced [41]. ASM and 
GCS mRNA and protein levels did not differ between parental and resistant 
cells (Fig. 8A, B). LNT-229 and LN-18 parental and resistant cells were then 
treated with increasing concentrations of TMZ. Significant differences 
between parental and resistant LNT-229 were found when cells were treated 
with TMZ in the range of 6 – 100 µM in an acute cytotoxicity assay (Fig. 8C) 
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and in the range of 3 – 100 µM in a clonogenicity assay (Fig. 8E). For LN-18 
parental and resistant cells, significant differences were observed for 30 µM 
and in the range of 250 - 1000 µM in an acute cytotoxicity assay (Fig. 8D) and 
in the range of 120 – 1000 µM in a clonogenicity assay (Fig. 8F). In a next 
step we assessed the cytotoxic effect of exogenous ceramide (C2-ceramide 
or C6-ceramide) or PPMP in parental and resistant cell lines. In both cell lines, 
LNT-229 and LN-18, exogenous ceramide as well as PPMP induced acute 
cytotoxicity (Fig. 8C, D) and decreased clonogenic survival (Fig. 8E, F) in a 
concentration-dependent manner, but without significant differences between 
parental and TMZ-resistant cells. 
 
Co-treatment with exogenous ceramide or PPMP and TMZ or irradiation 
shows additive but no synergistic effects in clonogenicity and acute 
cytotoxicity  assays in TMZ-resistant glioma cells  
Finally, we investigated whether co-treatment with PPMP or exogenous 
ceramide and TMZ could overcome resistance to TMZ in TMZ-resistant cells. 
Therefore LNT-229 and LNT-229_R cells were treated with a single 
concentration of PPMP (Fig. 9A) or C2-ceramide (Fig. 9B) or C6-ceramide 
(Fig. 9C) and different concentrations of TMZ for 24 h and were then cultured 
for additional 2 weeks until colony formation was detectable. The observed 
values matched with the predicted values for independent activities, in 
parental (as shown before) as well as in TMZ-resistant cell lines (Fig. 9A-C). 
The same occurred in LN-18 and LN-18_R cell lines (Fig. 9D), underscoring 
an additive but no synergistic effect of PPMP or exogenous ceramide in 
combination with TMZ, not only in parental but also in TMZ-resistant cell lines. 
To evaluate a possible synergy with irradiation in these TMZ-resistant cell 
lines, cells were irradiated and co-treated with PPMP, again demonstrating 
only additive effects in LNT-229 (Fig. 9E) and LN-18 (Fig. 9F) parental and 
resistant cells. To exclude that a synergistic effect would be detectable only in 
a short-time acute cytotoxicity assay, parental and TMZ-resistant cells were 
co-exposed to C2-ceramide, C6-ceramide or PPMP and TMZ for 72 h and cell 
density was measured using crystal violet staining in an acute cytotoxicity 
assay. When co-treatments were applied, however, the observed values in 
this acute cytotoxicity assay again matched the predicted values for 
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independent actions for LNT-229 and LNT-299_R (Fig. 9G) as well as for LN-
18 and LN-18_R (Fig.9H). 
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Discussion 
 
Ceramide is an important messenger initiating signal transduction pathways 
thought to promote tumor cell apoptosis in response to chemotherapy or 
irradiation [23,30,31,32]. Several studies demonstrated that exogenous C2-
ceramide induces apoptosis in almost any cell type, including human glioma 
cell lines [29]. However, the role of tumor cell endogenous ceramide levels for 
the primary resistance of glioma cells to the alkylating agents TMZ and CCNU 
as well as to radiation therapy requires a thorough investigation. We tested 
here whether modulation of ceramide levels in glioma cells themselves by 
ASM overexpression or PPMP treatment can overcome their resistance to 
TMZ, CCNU or irradiation. Surprisingly, modulations of intrinsic ceramide in 
human glioma cell lines trigger cytotoxicity, but do not synergistically enhance 
anti-tumor effects of TMZ or irradiation.  
Initially, we reasoned that tumors with poor outcome should be characterized 
by low levels of the ceramide-generating enzyme ASM and high levels of the 
ceramide-catabolizing enzyme GCS. In fact, low levels of ASM were 
associated with a better outcome in glioblastoma patients although ASM 
expression appeared not to be dramatically altered in gliomas of different 
grades of malignancies (Fig. 1). GCS mRNA levels in glioblastomas were not 
different compared to normal brain tissue (Fig. 1E). Of note, GCS mRNA 
levels were significantly lower in astrocytomas WHO grade II/III, not only 
compared to glioblastoma, but also to normal brain (Fig. 1E). Yet, 
glioblastoma patients with higher GCS mRNA levels had inferior survival (Fig. 
1H). Thus, increasing GSC mRNA correlates with ascending grades of 
malignancy, which may be reflected by low endogenous ceramide levels in 
high-grade gliomas [27] and increased GSC mRNA levels may characterize 
tumors that have a poor prognosis [35,56].  
We demonstrate that lentivirally induced ASM overexpression leads to 
increased endogenous ceramide levels and increased ASM activity in glioma 
cells, but does not affect proliferation (Fig. 2E), metabolic activity (Fig. 1F) or 
clonogenicity (Fig. 1G, H) of human glioma cells in vitro. Although it had been 
demonstrated that several stress stimuli resulted in ASM-induced ceramide 
accumulation leading to apoptosis [17,18,19], the stable ASM overexpression 
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and induction of endogenous ceramide did not lead to sensitization of glioma 
cells to clinically relevant therapies (Fig. 3).  
Interestingly, PPMP, a well-known GCS inhibitor [32] that promotes ceramide 
accumulation in human glioblastoma cell lines, induced cytotoxicity (Fig. 4C) 
and reduced clonogenicity (Fig. 4D). The cytotoxic effect of PPMP for 
glioblastomas is similar to previously published cytotoxic effects of this 
substance for colon cancer and breast cancer cells [57,58]. Cytotoxic effects 
correlated directly to the employed PPMP in a concentration-dependent 
manner and particularly to the induced ceramide concentrations. These 
results were in accordance with the anti-glioma effects of exogenous 
ceramide (Fig. 6) but were difficult to reconcile with the failure of ASM 
expression to induce cell death or to sensitize for TMZ, CCNU or irradiation 
(Fig. 3). In the light of these findings the impression is supported that a very 
early selection step after attempted ASM overexpression may promote the 
survival of cells resistant to ASM and therefore ceramide induction. However, 
the incorporation of amitriptyline, a functional ASM inhibitor during lentiviral 
transduction, did not change the observed effects in functional assays. The 
observed lack of evidence for an effect of ASM overexpression on 
sensitization of glioma cells to therapy is paralleled by the worse survival 
probability of glioblastoma patients with high levels of ASM in the TCGA 
database (Fig. 1D).  
Furthermore, the role of ASM overexpression or PPMP treatment for glioma 
resistance to current modalities of treatment was evaluated. Neither TMZ or 
CCNU nor irradiation led to synergistic anti-glioma effects in ASM-
overexpressing LNT-229 or T98G (Fig. 3, Fig. 5), although the additional 
treatment regime produced increased ceramide release (data not shown). For 
other cell lines and other chemotherapeutic drugs, a sensitizing effect of ASM 
activation was described [20,21,22]. Moreover, previous reports have 
suggested that PPMP sensitized tumor cells to various therapeutic agents 
[59]. However, no synergistic anti-glioma activity was detected in our 
experiments applying co-treatments of PPMP and TMZ. Combined therapy 
with PPMP and either TMZ or irradiation led to additive rather than synergistic 
effects in both glioma cell lines tested. On the other hand, the endogenous 
ceramide levels induced by ASM overexpression or PPMP treatment may not 
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have been in a dose range high enough to synergize with the added drug or 
additional irradiation effects. It seems also possible that there is a critical role 
of the ASM-ceramide system for chemotherapy-induced apoptosis, as shown 
for gemcitabine [32], but not for all therapeutic regimes, especially not for 
standard glioma treatments used for patients today. Alternatively, the 
subcellular localization of ceramide may determine the extent or type of 
damage that is induced.  
Moreover, the application of exogenous ceramide induced apoptosis in 
human glioblastoma cells [29], resulting in cytotoxicity and reduced 
clonogenicity in our glioblastoma cell lines (Fig. 6), but we did not observe a 
synergistic enhancement of irradiation- or TMZ-mediated apoptosis (Fig. 7, 
Fig. 8). Yet, the addition of exogenous ceramide may mimic only some of the 
signaling aspects of endogenous ceramide. These findings, of course, do not 
exclude a role of the ASM-ceramide system in the tumor microenvironment, 
i.e. the non-malignant cells in the glioma microenvironment in vivo, for 
sensitizing to irradiation and/or alkylating agents.  
In summary, efforts to modulate intrinsic ceramide levels by ASM 
overexpression or GCS inhibition by PPMP in glioma cells did not sensitize to 
alkylating chemotherapy or irradiation. Additionally, also exogenous ceramide 
applications did not result in synergistic effects with chemotherapeutics or 
irradiation in human glioma cells. These findings indicate that modulations of 
glioma cell intrinsic ceramide levels are not sufficient to overcome resistance 
to standard glioma therapies. We conclude that future studies on the role of 
modifications of ceramide in the glioma microenvironment for sensitization to 
irradiation or alkylating agents are warranted. This conclusion is supported by 
studies on experimental fibrosarcoma or melanoma in ASM-deficient mice. 
The tumors of these mice were resistant to radiation therapy in vivo. This 
phenotype was explained by the lack of radiation-induced ASM-mediated 
endothelial cell apoptosis in vivo [60] suggesting a role of host ASM for 
resistance to therapy. Thus, modulations of the ASM activity in the 
microenvironment in vivo, e.g. in the endothelial cell compartment, might be 
important for overcoming resistance to therapy in experimental gliomas. 
22 
Figure Legends 
 
Fig. 1 
ASM and GCS expression and clinical outcome in glioma patients 
(A) ASM mRNA expression was assessed in astrocytomas (WHO grades 
II/III) and glioblastomas, normalized to normal brain (Rembrandt database). 
Survival probabilities of patients with (B) astrocytoma (WHO grades II-IV) and 
(C) glioblastoma with at least 2-fold up-regulation of ASM (blue) compared 
with those of patients with intermediate expression of ASM (grey) (Rembrandt 
database). (D) Survival probabilities of patients with glioblastoma with high 
expression of ASM (blue) compared with those of patients with low expression 
of ASM (red) (TCGA database). (E) GCS mRNA expression of astrocytomas 
(WHO grades II/III) and glioblastomas, normalized to normal brain 
(Rembrandt database). Survival probabilities of patients with (F) astrocytoma 
(WHO grades II-IV) and (G) glioblastoma with at least 2-fold up-regulation of 
GCS (blue) or at least 2-fold down-regulation of GCS (red) (only in F) 
compared to those of patients with intermediate expression of GCS (grey) 
(Rembrandt database). (H) Survival probabilities of patients with glioblastoma 
with high expression of GCS (blue) compared with those of patients with low 
expression of GCS (red) (TCGA database). p-values were assessed using the 
log-rank test (p < 0.05 was considered significant). 
 
Fig. 2 
Stable overexpression of ASM increases ceramide levels in human glioma 
cell lines, but does not alter proliferation, metabolic activity or clonogenicity 
Assessment of lentiviral transduction efficacy by (A) fluorescence microscopy 
and (B) flow cytometry; wt, wild-type cells; SIEW, control-transduced cells; 
ASM, ASM-overexpressing cells. (C) ASM mRNA expression levels 
(statistically significant changes are marked with asterisks; **, p < 0.01; t-test) 
and (D) protein levels were assessed in wt, SIEW or ASM glioma cells. (E) 
Proliferation of LNT-229 or T98G wt, SIEW and ASM cells was measured up 
to 7 days by counting viable cells with trypan blue staining. One experiment 
out of three independent experiments is shown, all giving similar results. (F) 
Metabolic activity in these cell lines was assessed by Alamar Blue staining. 
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(G) Clonogenicity is presented for LNT-229 and T98G SIEW and ASM cells, 
normalized to wt cells. (H) One representative sample from (G) is shown for 
LNT-229 wt, SIEW control transduced and ASM overexpressing cells.  
 
Fig. 3 
ASM overexpression does not sensitize glioma cells to alkylating agents or 
irradiation in vitro 
Human glioma wt (open bars), SIEW (dark grey bars) or ASM (light grey bars) 
cells of (A, C, E) LNT-229 or (B, D, F) T98G were treated with increasing 
concentrations of (A, B) TMZ or (C, D) CCNU for 24 h or increasing doses of 
(E, F) irradiation. Statistically significant changes compared to untreated cells 
are marked with asterisks (*, p < 0.05; **, p < 0.01; t-test). 
 
Fig. 4 
PPMP reduces acute cytotoxicity and clonogenic survival in human glioma 
cell lines  
(A) GCS mRNA and (B) protein expression were assessed in LNT-229 and 
T98G human glioma cells. ARF1 was used as housekeeping gene for mRNA 
measurements and GAPDH for immunoblot analyses. (C) Acute cytotoxicity 
was assessed 72 h after treatment with increasing concentrations of PPMP in 
these glioma cells. (D) For clonogenic survival data LNT-229 or T98G cells 
were treated with increasing concentrations of PPMP for 24 h, the medium 
was changed and cells were cultured for additional 2 weeks until colonies 
were detectable. Statistically significant changes compared to untreated cells 
are marked with asterisks (*, p < 0.05; **, p < 0.01; t-test). 
 
Fig. 5 
Co-treatment with PPMP and TMZ or irradiation shows additive but not 
synergistic effects in vitro 
(A) LNT-229 or (B) T98G wt cells were treated with increasing concentrations 
of TMZ or PPMP or co-treated with both agents for 24 h and clonogenicity 
assessed 2 – 3 weeks later. (C) LNT-229 or (D) T98G wild-tye cells were 
treated with increasing concentrations of PPMP for 24 h and increasing doses 
of RT or co-treated with PPMP and irradiation and clonogenicity data obtained 
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2 – 3 weeks later. (E) LNT-229 or (F) T98G wt cells were treated with a single 
dose of PPMP (5 µM) or TMZ (LNT-229:  12 µM; T98G: 125 µM) for 72 h or 
RT (8 Gy) or co-treated with PPMP and TMZ or RT and cell density measured 
with crystal violet 72 h later. Predicted values, assessed using the fractional 
product method, are displayed in grey bars, observed values are highlighted 
by blank bars. Statistically significant changes compared to untreated cells 
are marked with asterisks (*, p < 0.05; **, p < 0.01; t-test). 
 
Fig. 6 
Exogenous ceramide is cytotoxic to human glioma cell lines and reduces 
clonogenic survival 
Acute cytotoxicity was assessed 72 h after treatment with increasing 
concentrations of (A) C2-ceramide or (B) C6-ceramide in LNT-229 or T98G 
cells. For clonogenic survival data LNT-229 or T98G cells were treated with 
increasing concentrations of (C) C2-ceramide or (D) C6-ceramide for 24 h, 
then medium was changed and cells were cultured for additional 2 weeks until 
colonies were detectable. *, p < 0.05; **, p < 0.01; compared to untreated 
cells; t-test. 
 
Fig. 7 
Co-treatment with exogenous ceramide or TMZ or irradiation shows additive 
but not synergistic effects in vitro 
(A) LNT-229 or (B) T98G wt cells were treated with increasing concentrations 
of TMZ or C2- or C6-ceramide or co-treated with TMZ and C2- or C6-
ceramide for 24 h and clonogenicity was assessed 2 – 3 weeks later. (C) 
LNT-229 or (D) T98G wt cells were treated with increasing concentrations of 
C2- or C6-ceramide for 24 h and increasing doses of irradiation (RT) or co-
treated with C2- or C6-ceramide and irradiation and clonogenicity data were 
obtained 2 – 3 weeks later. (E) LNT-229 or (F) T98G wt cells were treated 
with a single dose of C2-ceramide (12 µM), C6-ceramide (12 µM) or TMZ 
(LNT-229:  12 µM; T98G: 125 µM) for 72 h or RT (8 Gy) or co-treated with C2- 
or C6-ceramide and TMZ or RT and cell density measured with crystal violet 
72 h later. Predicted values, assessed using the fractional product method, 
are displayed in grey bars, observed values are highlighted by blank bars. 
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Statistically significant changes compared to untreated cells are marked with 
asterisks (*, p < 0.05; **, p < 0.01; t-test). 
 
Fig. 8 
Exogenous ceramide and PPMP are cytotoxic to human glioma cell lines 
resistant to TMZ and reduce clonogenic survival 
ASM and GCS (A) mRNA expression levels and (B) protein levels were 
assessed in LNT-229 and LN-18 parental and TMZ-resistant cell lines. Acute 
cytotoxicity in (C) LNT-229 and LNT-229_R and in (D) LN-18 and LN-18_R 
cell lines was assessed 72 h after treatment with increasing concentrations of 
TMZ, PPMP, C2-ceramide or C6-ceramide. For clonogenic survival data (E) 
LNT-229 and LNT-229_R or (F) LN-18 and LN-18_R cells were treated with 
increasing concentrations of TMZ, PPMP, C2-ceramide or C6-ceramide for 24 
h, then medium was changed and cells were cultured for additional 2 weeks 
until colonies were detectable. Parental cells are highlighted by black squares, 
resistant cells are highlighted by grey squares. Statistically significant 
changes compared to untreated cells are marked with asterisks (*, p < 0.05; 
**, p < 0.01; t-test), statistically significant changes of parental to resistant 
cells are marked with open triangles (, p < 0.05; , p < 0.01; t-test). 
 
Fig. 9 
Co-treatment with exogenous ceramide or PPMP and TMZ or irradiation 
shows additive but no synergistic effects in clonogenicity and acute 
cytotoxicity assays in TMZ-resistant glioma cells. LNT-229 and LNT-229_R 
cells were treated with (A) PPMP or TMZ or co-treated with PPMP and TMZ 
or (B) C2-ceramide or TMZ or co-treated with C2-ceramide or (C) C6-
ceramide or TMZ or co-treated with C6-ceramide and TMZ for 24 h, the 
medium was then changed and cells were cultured for additional 2 weeks until 
colonies were detectable. (D) LN-18 and LN-18_R cells were treated with 
PPMP or C2-ceramide or C6-ceramide or co-treated with PPMP or C2-
ceramide or C6-ceramide for 24 h, the medium was then changed and cells 
were cultured for additional 2 weeks until colonies were detectable. (E) LNT-
229 and LNT-229_R or (F) LN-18 and LN-18_R cells were treated with RT or 
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PPMP or co-treated with PPMP for 24 h and RT. Clonogenicity data were 
assessed 2 weeks later colonies were detectable. (G) LNT-229 and LNT-
229_R or (H) LN-18 and LN-18_R cells were treated with C2-ceramide, C6-
ceramide, PPMP or TMZ alone or co-treated. Cell density was measured by 
crystal violet staining 72 h later. Parental cells are marked with white bars, 
resistant cells are marked with grey bars. Predicted values, assessed using 
the fractional product method, are highlighted in dotted bars, observed values 
are displayed by undotted bars. Statistically significant changes in resistant 
cells compared to wt cells are marked with asterisks (*, p < 0.05; **, p < 0.01; 
t-test). 
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